Trial Profile
An efficacy study of addition of telaprevir or boceprevir to peginterferon alfa/ribavirin (peg-alfa/RBV) regimens for the treatment of hepatitis C in clinical practice
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 13 Dec 2015
Price :
$35
*
At a glance
- Drugs Boceprevir (Primary) ; Telaprevir (Primary) ; Peginterferon alfa; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 13 Dec 2015 New trial record